Vice Provost and Dean of Research


Showing 81-90 of 196 Results

  • Brian Hie

    Brian Hie

    Assistant Professor of Chemical Engineering

    BioI am an Assistant Professor of Chemical Engineering at Stanford University, the Dieter Schwarz Foundation Stanford Data Science Faculty Fellow, and an Innovation Investigator at Arc Institute. I supervise the Laboratory of Evolutionary Design, where we conduct research at the intersection of biology and machine learning.

    I was previously a Stanford Science Fellow in the Stanford University School of Medicine and a Visiting Researcher at Meta AI. I completed my Ph.D. at MIT CSAIL and was an undergraduate at Stanford University.

  • Michael R. Howitt

    Michael R. Howitt

    Assistant Professor of Pathology and of Microbiology and Immunology
    On Leave from 02/16/2026 To 07/17/2026

    Current Research and Scholarly InterestsOur lab is broadly interested in how intestinal microbes shape our immune system to promote both health and disease. Recently we discovered that a type of intestinal epithelial cell, called tuft cells, act as sentinels stationed along the lining of the gut. Tuft cells respond to microbes, including parasites, to initiate type 2 immunity, remodel the epithelium, and alter gut physiology. Surprisingly, these changes to the intestine rely on the same chemosensory pathway found in oral taste cells. Currently, we aim to 1) elucidate the role of specific tuft cell receptors in microbial detection. 2) To understand how protozoa and bacteria within the microbiota impact host immunity. 3) Discover how tuft cells modulate surrounding cells and tissue.

  • KC Huang

    KC Huang

    LeRa Professor and Professor of Microbiology and Immunology
    On Leave from 01/01/2026 To 03/31/2026

    Current Research and Scholarly InterestsHow do cells determine their shape and grow?
    How do molecules inside cells get to the right place at the right time?

    Our group tries to answer these questions using a systems biology approach, in which we integrate interacting networks of protein and lipids with the physical forces determined by the spatial geometry of the cell. We use theoretical and computational techniques to make predictions that we can verify experimentally using synthetic, chemical, or genetic perturbations.

  • Adrian Hugenmatter

    Adrian Hugenmatter

    Director of Protein Engineering

    BioDr. Adrian Hugenmatter joined ChEM-H as Director of Protein Engineering in 2021. In his role, Dr. Hugenmatter heads the Protein Engineering Laboratory at the Nucleus and is responsible for the development of therapeutic proteins at the Innovative Medicines Accelerator (IMA). Dr. Hugenmatter obtained his PhD in the laboratory of Prof. Donald Hilvert at the Swiss Federal Institute of Technology in Zurich (ETH Zurich, Switzerland), where he gained initial experience in the fields of enzymology, antibody engineering and directed evolution. Fascinated by protein engineering, he moved to the laboratory of Prof. Dan Tawfik at the Weizmann Institute of Science (Israel), where he studied molecular evolution and its application in protein design. Dr. Hugenmatter then worked for more than a decade as a researcher and team leader at Roche. During this time, he was involved in the development and optimization of several antibody lead candidates for therapeutic applications in neuroscience and oncology.

  • Paul S Humphries

    Paul S Humphries

    Alliance Director, Innovative Medicines Accelerator (IMA)

    Current Role at StanfordAlliance Director, Stanford Innovative Medicines Accelerator (IMA)

  • Peter K.  Jackson

    Peter K.  Jackson

    Professor of Microbiology and Immunology (Baxter Labs) and of Pathology

    Current Research and Scholarly InterestsCell cycle and cyclin control of DNA replication .

  • Christine Jacobs-Wagner

    Christine Jacobs-Wagner

    Dennis Cunningham Professor, Professor of Biology and of Microbiology and Immunology

    BioChristine Jacobs-Wagner is a Dennis Cunningham Professor in the Department of Biology and the ChEM-H Institute at Stanford University. She is interested in understanding the fundamental mechanisms and principles by which cells, and, in particular, bacterial cells, are able to multiple. She received her PhD in Biochemistry in 1996 from the University of Liège, Belgium where she unraveled a molecular mechanism by which some bacterial pathogens sense and respond to antibiotics attack to achieve resistance. For this work, she received multiple awards including the 1997 GE & Science Prize for Young Life Scientists. During her postdoctoral work at Stanford Medical School, she demonstrated that bacteria can localize regulatory proteins to specific intracellular regions to control signal transduction and the cell cycle, uncovering a new, unsuspected level of bacterial regulation.

    She started her own lab at Yale University in 2001. Over the years, her group made major contributions in the emerging field of bacterial cell biology and provided key molecular insights into the temporal and spatial mechanisms involved in cell morphogenesis, cell polarization, chromosome segregation and cell cycle control. For her distinguished work, she received the Pew Scholars award from the Pew Charitable Trust, the Woman in Cell Biology Junior award from the American Society of Cell Biology and the Eli Lilly award from the American Society of Microbiology. She held the Maxine F. Singer and William H. Fleming professor chairs at Yale. She was elected to the Connecticut academy of Science, the American Academy of Microbiology and the National Academy of Sciences. She has been an investigator of the Howard Hughes Medical Institute since 2008.

    Her lab moved to Stanford in 2019. Current research examines the general principles and spatiotemporal mechanisms by which bacterial cells replicate, using Caulobacter crescentus and Escherichia coli as models. Recently, the Jacobs-Wagner lab expanded their interests to the Lyme disease agent Borrelia burgdorferi, revealing unsuspected ways by which this pathogen grows and causes disease

  • Amy Jacobson

    Amy Jacobson

    Director of Microbiome Therapies, Microbiome Therapies Initiative (MITI)

    Current Role at StanfordSenior Scientific Program Manager, Sarafan ChEM-H and Stanford Innovative Medicines Accelerator